Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback